H.C. Wainwright upped the firm’s rating on Motus GI Holdings to Under Review from Buy. While the Pure-Vu EVS Gastro and Gen 4 Colon system could drive market adoption and revenue growth, the current market capitalization of Motus shares at $1.5M may limit the company’s ability to raise additional capital, which may then result in substantial doubt about continuing as a going concern, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MOTS:
- Motus GI Holdings price target lowered to $8.30 from $20.25 at Alliance Global Partners
- Motus GI Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Motus GI Holdings announces use of FDA cleared Pure-Vu EVS Gastro
- Motus GI Holdings announces 1-for-15 reverse stock split
- Motus receives FDA clearance to commercialize Pure-Vu EVS Gastro, Gen 4 Colon